Medpace (NASDAQ:MEDP) Shares Up 1.9%

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) traded up 1.9% during mid-day trading on Tuesday . The company traded as high as $408.43 and last traded at $408.43. 29,898 shares traded hands during trading, a decline of 88% from the average session volume of 246,589 shares. The stock had previously closed at $400.74.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on MEDP shares. Jefferies Financial Group raised Medpace from a "hold" rating to a "buy" rating and raised their price target for the stock from $340.00 to $450.00 in a report on Tuesday, April 23rd. StockNews.com raised Medpace from a "hold" rating to a "buy" rating in a report on Tuesday, April 23rd. Robert W. Baird increased their price target on shares of Medpace from $446.00 to $454.00 and gave the stock an "outperform" rating in a report on Wednesday, April 24th. Guggenheim raised their price objective on shares of Medpace from $453.00 to $464.00 and gave the company a "buy" rating in a research report on Wednesday, April 24th. Finally, UBS Group raised shares of Medpace from a "neutral" rating to a "buy" rating and upped their target price for the stock from $282.00 to $452.00 in a report on Thursday, February 15th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $443.00.

Medpace Stock Up 0.3 %

The firm's 50-day simple moving average is $398.00 and its 200-day simple moving average is $334.20. The firm has a market capitalization of $12.46 billion, a P/E ratio of 40.99, a price-to-earnings-growth ratio of 1.95 and a beta of 1.40.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The company had revenue of $511.00 million during the quarter, compared to analyst estimates of $512.39 million. During the same period in the previous year, the business earned $2.27 earnings per share. The firm's quarterly revenue was up 17.7% compared to the same quarter last year. As a group, analysts expect that Medpace Holdings, Inc. will post 11.23 EPS for the current fiscal year.

Insider Buying and Selling at Medpace

In other Medpace news, major shareholder Medpace Investors, Llc sold 50,000 shares of the company's stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $391.75, for a total transaction of $19,587,500.00. Following the completion of the sale, the insider now directly owns 5,539,947 shares in the company, valued at $2,170,274,237.25. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other Medpace news, major shareholder Medpace Investors, Llc sold 50,000 shares of the firm's stock in a transaction on Friday, February 16th. The shares were sold at an average price of $391.75, for a total value of $19,587,500.00. Following the sale, the insider now owns 5,539,947 shares of the company's stock, valued at approximately $2,170,274,237.25. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO August J. Troendle sold 100,000 shares of the company's stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total value of $41,298,000.00. Following the transaction, the chief executive officer now directly owns 4,833,019 shares of the company's stock, valued at approximately $1,995,940,186.62. The disclosure for this sale can be found here. Insiders have sold 204,442 shares of company stock worth $82,702,867 over the last ninety days. Insiders own 20.30% of the company's stock.

Institutional Trading of Medpace

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rise Advisors LLC bought a new stake in Medpace in the 1st quarter worth about $27,000. Mather Group LLC. purchased a new position in shares of Medpace during the first quarter valued at approximately $28,000. Fidelis Capital Partners LLC purchased a new stake in Medpace in the first quarter worth approximately $31,000. Contravisory Investment Management Inc. bought a new stake in Medpace in the 4th quarter worth approximately $26,000. Finally, RiverPark Advisors LLC bought a new stake in Medpace in the 4th quarter worth approximately $26,000. Hedge funds and other institutional investors own 77.98% of the company's stock.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.